Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.75
$3.93
52-Week Range
N/A
Volume
63,385 shs
Average Volume
81,306 shs
Market Capitalization
$45.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics Rebrands As Rein Therapeutics
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

Shares of Aileron Therapeutics reverse split before market open on Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
CIK
1420565
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.08%
Return on Assets
-27.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.30
Quick Ratio
3.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
21,670,000
Free Float
20,561,000
Market Cap
$45.72 million
Optionable
Not Optionable
Beta
2.24

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners